Latest total current liabilities for BRNS: $12M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Barinthus Biotherapeutics Plc. (BRNS) currently reports a total current liabilities of $12M as of March 2026. That compares with $12M in the prior-year period — up 0.2% year over year. Use the charts on this page to explore Barinthus Biotherapeutics Plc.'s total current liabilities history and peer comparisons.
Barinthus Biotherapeutics Plc.'s total current liabilities increased from $12M to $12M — a 0.2% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Barinthus Biotherapeutics Plc. reported $12M in total current liabilities as of March 2026. That compares with $12M in the prior-year period — up 0.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current total current liabilities of $12M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Barinthus Biotherapeutics Plc., and consider following BRNS for alerts when major investors trade the stock.
Barinthus Biotherapeutics Plc. is classified in the Healthcare sector. On total current liabilities, it currently shows $12M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BRNS with unrelated industries.